Compare Summit Therapeutics Inc (SMMT) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Summit Therapeutics Inc trades at $15.2 (market cap $12.06B), while NEOS S&P 500 High Income ETF trades at $54.23. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | SPYI | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $26.98 | $54.19 |
52-Week Low | $12.55 | $47.98 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
SPYI trades at $54.23, up 0.07% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, offering a distribution yield near 12%. Recent news highlights its appeal for retirement income but raises concerns about fee gaps and potential over-reliance on volatility for payouts.
The outlook is mixed: SPYI provides tax-efficient yield for income investors but faces risks from declining volatility and capital erosion. Wall Street debates sustainability, with some analysts bullish on its strategy while others warn of hidden costs. Investors should weigh high distributions against long-term principal preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
